-
2024-514248-95-00
5
Uncontrolled Asthma
-
2024-517861-18-00
5
Idiopathic IgA nephropathy (IgAN)
-
2024-518026-32-00
5
Invasive Breast Cancer
-
2024-519087-41-00
5
Breast cancer is the most common form of cancer among women in North A
-
2024-519519-32-00
4
urothelial cancer
-
2025-523793-16-00
4
Homeostatic iron regulator gene-related hereditary hemochromatosis
-
2024-519623-23-00
5
2025-10-20
Venous leg ulcer
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2025-522786-29-00
4
2026-01-07
Spastic Cerebral Palsy
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT
-
2024-514031-20-00
4
2025-02-24
Inoperable locally advanced or metastatic TNBC patients, previously tr
-
2024-516841-38-00
4
2025-01-09
recurrent ovarian cancer wild type for germline and somatic BRCA 1 and
-
2024-516839-27-00
4
2024-12-09
BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2023-505078-13-00
4
2024-01-16
EXTENSIVE STAGE ‐ EXTRAPULMONARY SMALL CELL CARCINOMA
-
2024-518534-81-00
4
2021-07-01
metastatic colorectal cancer
-
2023-510515-19-00
5
2020-11-27
Higher-risk-myelodysplastic syndromes
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2024-517200-10-00
4
2020-01-31
Advanced non-small-cell lung cancer
-
2024-513372-18-00
4
2019-10-18
Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
-
2024-512747-23-00
5
2024-07-30
Transfusion-Dependent Alpha- or Beta-Thalassemia
-
2022-502446-27-00
5
2024-02-26
Relapsed or Refractory Myeloma
-
2024-512745-16-00
5
2022-04-13
Non–Transfusion-Dependent Alpha- or Beta-Thalassemia